Saturn V Capital Management

Saturn V Capital Management is a hedge fund and investment adviser based in Austin, Texas. The firm specializes in long/short public equity investments with a focus on biotechnology companies that have upcoming binary clinical readouts. Founded in late 2021 by Xiaoying Tian, who serves as the primary portfolio manager, the firm has grown rapidly to manage approximately $400 million in assets under management as of early 2025. The team consists of three investment professionals and one operating professional. Saturn V invests primarily in publicly traded biotech companies and does not itself conduct drug development or clinical trials.